These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24625885)

  • 21. Verification bias and the prostate-specific antigen test--is there a case for a lower threshold for biopsy?
    Schröder FH; Kranse R
    N Engl J Med; 2003 Jul; 349(4):393-5. PubMed ID: 12878747
    [No Abstract]   [Full Text] [Related]  

  • 22. Role of free prostate-specific antigen measurement in prostate-specific antigen screening for prostate cancer.
    Johnson L
    Clin Prostate Cancer; 2002 Dec; 1(3):142-4. PubMed ID: 15046688
    [No Abstract]   [Full Text] [Related]  

  • 23. Editorial comment to association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy.
    Shimbo M
    Int J Urol; 2012 Aug; 19(8):747-8. PubMed ID: 22651131
    [No Abstract]   [Full Text] [Related]  

  • 24. [Standards for the punch biopsy of the prostate].
    Seitz M; Schlenker B; Gratzke C; Weidlich P; Stief CG; Reich O
    MMW Fortschr Med; 2007 Jan; 149(4):35-6. PubMed ID: 17615715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
    Pushkar' DIu; Rasner PI; Skobelev PP
    Urologiia; 2001; (6):48-54. PubMed ID: 11785083
    [No Abstract]   [Full Text] [Related]  

  • 26. PSA: the plot thickens.
    Health News; 2003 Oct; 9(10):15. PubMed ID: 14619777
    [No Abstract]   [Full Text] [Related]  

  • 27. Editorial comment. Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.
    Autorino R; Perdonà S; Di Lorenzo G
    Urology; 2010 Nov; 76(5):1076; author reply 1076-7. PubMed ID: 21056255
    [No Abstract]   [Full Text] [Related]  

  • 28. Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer.
    Kaplan SA; Lee RK; Chung DE; Te AE; Scherr DS; Tewari A; Vaughan ED
    J Urol; 2012 Sep; 188(3):757-61. PubMed ID: 22818135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The quest for the perfect prostate biopsy continues.
    Gomella LG
    J Urol; 2012 Jun; 187(6):1954-5. PubMed ID: 22503025
    [No Abstract]   [Full Text] [Related]  

  • 30. Editorial: Lessons learned from prostate biopsies.
    McCullough DL
    J Urol; 2002 Nov; 168(5):2000. PubMed ID: 12394694
    [No Abstract]   [Full Text] [Related]  

  • 31. Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies?
    Klein EA
    J Urol; 1996 Aug; 156(2 Pt 1):443-4. PubMed ID: 8683698
    [No Abstract]   [Full Text] [Related]  

  • 32. The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA.
    Stamey TA
    BJU Int; 2004 Nov; 94(7):963-4. PubMed ID: 15541106
    [No Abstract]   [Full Text] [Related]  

  • 33. Biopsy of the prostate--an ongoing evolution.
    Macchia RJ
    J Urol; 2004 Apr; 171(4):1487-8. PubMed ID: 15017204
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?
    Ansari MS
    J Urol; 2002 Jul; 168(1):200; author reply 200-1. PubMed ID: 12050532
    [No Abstract]   [Full Text] [Related]  

  • 35. The application of p2PSA% and prostate health index in prostate cancer detection: A prospective cohort in a Tertiary Medical Center.
    Cheng YT; Chiang CH; Pu YS; Liu SP; Lu YC; Chang YK; Chang HC; Huang KH; Lee YJ; Chow PM; Hung SC; Huang CY
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):260-267. PubMed ID: 29779925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The influence of prostate volume on the diagnostic parameters related to PSA and clinicopathological features of prostate cancer].
    Kimura G; Kimata R; Saito Y; Yoshida K; Nishimura T
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():479-85. PubMed ID: 12599623
    [No Abstract]   [Full Text] [Related]  

  • 37. Impacts of the COVID-19 pandemic on early detection of prostate cancer in Australia.
    Ip CCK; Kealey J; Davis ID; Sengupta S
    BJU Int; 2021 Dec; 128 Suppl 3(Suppl 3):6-8. PubMed ID: 34750958
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of cancer detection between 18- and 12-core prostate biopsy in Asian patients with prostate-specific antigen levels of 4-20 ng/mL.
    Wang BR; Chen CC; Zheng RH; Hu JC; Ou YC
    J Chin Med Assoc; 2018 Dec; 81(12):1044-1051. PubMed ID: 30100355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Words of wisdom. Re: PSA density improves prediction of prostate cancer.
    Roobol MJ
    Eur Urol; 2014 Nov; 66(5):964-5. PubMed ID: 25763443
    [No Abstract]   [Full Text] [Related]  

  • 40. Comments on the article "Biomarkers for prostate cancer" by Eric Schiffer.
    Marshall S
    World J Urol; 2009 Aug; 27(4):577-8. PubMed ID: 19543735
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.